Anti-leukemic activity of Luveltamab tazevibulin (LT, STRO-002), a novel Folate receptor-α (FR-α)-targeting antibody drug conjugate (ADC) in relapsed/refractory CBF2AT3::GLIS2 AML Meeting Abstract
| Authors: | Williams, R.; Miller, L.; Massaro, S.; Krieger, E.; Pauly, M.; Nelson, C.; Johnson, R.; Welch, J. J. G.; Bhojwani, D.; Moghimi, B.; Neff, P.; Horton, T. M.; Imran, H.; Ribeiro, R. C.; Guinipero, T. L.; Kutny, M. A.; Bautista, F.; Johnson, A.; Lewing, K.; Gamis, A. S.; Brackett, J.; McCall, D.; Bhatla, T.; Sulis, M. L.; Tellinghuisen, A.; Beck, J. C.; Meshinchi, S. |
| Abstract Title: | Anti-leukemic activity of Luveltamab tazevibulin (LT, STRO-002), a novel Folate receptor-α (FR-α)-targeting antibody drug conjugate (ADC) in relapsed/refractory CBF2AT3::GLIS2 AML |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 4295 |
| Language: | English |
| ACCESSION: | WOS:001159740307041 |
| DOI: | 10.1182/blood-2023-180141 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
